Gene · 1585
Papers3,065
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,065
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Bilateral adrenal adenomas presenting with ACTH-independent Cushing's syndrome and primary aldosteronism: diagnostic insights from multi-steroid adrenal venous sampling. | Front Endocrinol (Lausanne) | 2026 | 42609288 | PubTator, text mining | PubMed |
| Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio: first evaluation in clinical routine. | Histopathology | 2026 | 42549509 | PubTator, text mining | PubMed |
| [Primary aldosteronism as an independent factor of kidney damage. Potential therapeutic strategies and research prospects]. | Probl Endokrinol (Mosk) | 2026 | 42545319 | PubTator, text mining | PubMed |
| Mineralocorticoid receptor overactivation in heart failure with preserved ejection fraction. | Eur Heart J | 2026 | 42543746 | PubTator, text mining | PubMed |
| Efficacy and Safety of Selective Aldosterone Synthase Inhibitors in Uncontrolled Hypertension: A Systematic Review and Dose-Specific Network Meta-Analysis of Randomized Controlled Trials. | Cardiol Rev | 2026 | 42535833 | PubTator, text mining | PubMed |
| Can baxdrostat redefine blood pressure control in resistant and uncontrolled hypertension? a systematic review, meta-analysis, and trial sequential analysis. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42521822 | PubTator, text mining | PubMed |
| Selective Aldosterone Synthase Inhibition in Resistant and Uncontrolled Hypertension: Focus on Lorundrostat. | J Cardiovasc Pharmacol | 2026 | 42520394 | PubTator, text mining | PubMed |
| Changes in the Adrenal Cortex Induced by Liraglutide Treatment and Exercise in a Rat Model of Menopausal Transition. | Cells | 2026 | 42505368 | PubTator, text mining | PubMed |
| Apiotrichum-Centered Fungal Interaction Network Disturbance Correlates With Increased Arterial Stiffness. | Aging Cell | 2026 | 42502257 | PubTator, text mining | PubMed |
| Efficacy and safety of baxdrostat add-on in uncontrolled and resistant hypertension: a systematic review and meta-analysis of randomized controlled trials with GRADE certainty-of-evidence assessment. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | 42484857 | PubTator, text mining | PubMed |
| Baxdrostat and selective aldosterone synthase inhibition in hard-to-control hypertension: mechanism, evidence, safety, and future clinical positioning. | Expert Opin Pharmacother | 2026 | 42467440 | PubTator, text mining | PubMed |
| Targeting the Renin-Angiotensin-Aldosterone System: Preclinical and Clinical Developments. | Circ Res | 2026 | 42461993 | PubTator, text mining | PubMed |
| Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors. | Circ Res | 2026 | 42461992 | PubTator, text mining | PubMed |
| Aldosterone in Diabetic Kidney Disease: From Mineralocorticoid Receptor Antagonism to Aldosterone Synthase Inhibition. | Int J Mol Sci | 2026 | 42449939 | PubTator, text mining | PubMed |
| Targeting Aldosterone Biosynthesis in Uncontrolled and Resistant Hypertension: A Systematic Review and Meta-Analysis of Randomized Trials of Lorundrostat and Baxdrostat. | J Cardiovasc Pharmacol Ther | 2026 | 42439807 | PubTator, text mining | PubMed |
| Novel gain-of-function CLCN2 germline mutation associated with nonclassical lateralizing primary aldosteronism. | J Mol Endocrinol | 2026 | 42439370 | PubTator, text mining | PubMed |
| Adrenocortical oncocytoma manifesting as primary aldosteronism: a case report. | Blood Press | 2026 | 42439312 | PubTator, text mining | PubMed |
| Aldosterone Synthase Inhibition in Diabetes and Cardiorenal Metabolic Disease. | J Diabetes | 2026 | 42432386 | PubTator, text mining | PubMed |
| Liddle syndrome caused by SCNN1B mutation presenting with severe early-onset hypertension and hypokalemia in an adolescent: a case report. | BMC Endocr Disord | 2026 | 42426704 | PubTator, text mining | PubMed |
| miR-486-5p and miR-144-3p as candidate regulators of cortisol biosynthesis: functional and transcriptomic evidence in adrenocortical cells. | Eur J Endocrinol | 2026 | 42417506 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1585/papers?page=2